Early @entity328 serotype changes in Utah adults after the introduction of PCV13 in XXXX .

@entity1 @entity2506 @entity693 @entity3 @entity1485 @entity328
INTRODUCTION: Pneumococcal conjugate vaccines ( @entity1485 ) have indirect effects due to decreased @entity328 colonization in vaccine recipients. We sought to determine whether the introduction of PCV13 in @entity1 led to changes in the epidemiology and clinical manifestations of @entity3 ( @entity3 ) in adults. METHODS: We described demographics, comorbidities, clinical manifestations, and serotypes of @entity3 in Utah adults before (November 2009-February 2010) and after (March 2010-March 2012) the introduction of PCV13 in @entity1 . We also compare serotypes causing @entity3 in Utah adults and @entity1 . RESULTS: After the introduction of PCV13 in the childhood vaccine program, the proportion of @entity3 due to PCV13 exclusive serotypes decreased significantly in Utah adults (64-40%, p=0.009), primarily due to a decline in serotype 7F (36-15%, p=0.008). There were non-significant increases in @entity3 due to Pneumococcal polysaccharide 23 (PPV23) unique serotypes and non-vaccine serotypes, most notably serotype 22F. Changes in the proportions of vaccine and non-vaccine serotypes were similar in adults and @entity1 . @entity693 was more commonly due to non-vaccine serotypes relative to @entity693 cases (47% vs. 18%, p=0.007). When stratified by sex, decreases in PCV13 serotype @entity3 were only noted in @entity1 (76-33%, p=0.001). CONCLUSIONS: Serotype epidemiology of @entity3 in adults closely follows that of @entity1 in the PCV13 era. Continued surveillance is needed to confirm whether replacement serotypes will lead to increases in @entity2506 and whether there are sex differences in the indirect effects of @entity1485 vaccination in @entity1 .
